Typical weight loss with Mounjaro: what the trial results actually show

Imagine you've just started Mounjaro and you're wondering when the number on the scale will move

The first pen contains 2.5mg, and that dose is calibrated for tolerance, not for dramatic early losses. Its job is to let your body adjust to a new way of regulating appetite and gastric emptying. Some people do see the scale shift in the first week, usually a combination of reduced food intake, less water retention, and slower stomach emptying. Others don't. Both are normal at this stage.

A common misconception is that slow early progress means Mounjaro isn't working. It doesn't. The medicine's mechanism, activating both the GIP and GLP-1 receptors to reduce hunger and slow digestion, takes time to exert its full effect as the dose is increased. By the time most people reach a maintenance dose, appetite suppression is meaningfully stronger than at 2.5mg. If you're a few weeks in and the scale is quiet, you may find it reassuring to read about early stalls specifically.

The NHS tirzepatide pages confirm that weight reduction typically becomes more consistent as dose titration progresses, and the NHS medicines information for tirzepatide outlines what to expect during treatment.

What the SURMOUNT-1 numbers mean for someone sitting at home with a pen in the fridge

SURMOUNT-1 randomised 2,539 adults with obesity (and no diabetes) to tirzepatide or placebo over 72 weeks. At the 15mg dose, average weight loss was around 20–21% of body weight, with some analyses reaching approximately 22.5%. For a person starting at 100kg, that translates to roughly 20–22kg over a year and a half. At 10mg the average was around 19.5%; at 5mg, around 15%.

These are averages. Some participants lost more; some lost less. The people who did best tended to combine the medicine with genuine changes to eating patterns and regular physical activity, exactly as the licence requires. The trial also involved structured lifestyle support throughout, so the numbers reflect tirzepatide alongside behaviour change, not tirzepatide instead of it.

Typical weight loss on Mounjaro also depends on which dose you ultimately reach. Not everyone titrates to 15mg; some people tolerate lower doses better and stay there. A prescriber will factor in how you're responding, both in terms of weight loss and side effects, before recommending any dose change. More detail on the broader results picture is on our weight loss on Mounjaro page.

Why two people on the same dose can see very different results

Genetics, gut microbiome composition, baseline insulin sensitivity, how much lean muscle mass someone carries, sleep quality, stress levels, all of these influence how the body responds to tirzepatide. So does adherence: missing doses or increasing food intake to compensate for reduced nausea can blunt the medicine's effect. The timeline to meaningful results varies considerably between individuals for these reasons.

Age matters too. Older adults tend to lose a smaller percentage of weight on average, partly because of hormonal differences and partly because of changes in metabolic rate. People with type 2 diabetes tend to lose somewhat less than those without, though weight reduction is still clinically meaningful. NICE's appraisal of tirzepatide, published as NICE technology appraisal TA1026, discusses both the evidence base and the populations in which it was studied.

If progress has stalled after a reasonable period on a stable dose, the first question is whether more can be learned from the pattern. Our page on no weight loss on Mounjaro walks through the most common reasons and what a prescriber might consider.

Putting the numbers in context before you start

A 20% average weight reduction is substantially more than was achievable with any previous licensed weight medicine in the UK. It is also not a ceiling: the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes, the first properly powered direct comparison between the two medicines.

None of this means outcomes are uniform or predictable. The honest framing is that Mounjaro shifts the odds considerably in favour of meaningful weight loss for people who are clinically suitable, use it consistently alongside lifestyle changes, and titrate to a dose that works for them. What it cannot do is override a diet that consistently exceeds appetite-suppressed intake, or substitute for sleep, activity, or stress management.

Cost is a practical part of the picture too. If you want to understand what private treatment involves financially, our Mounjaro cost page sets out what to look for when comparing providers. When you're ready to explore whether treatment is right for you, starting a free consultation with our prescribers is the natural next step, a real clinician reviews every application the same day.